Neo Performance Materials Q2 Earnings Call Highlights

Neo Performance Materials TSE: NEO reported record second-quarter results, citing higher volumes, favorable pricing and lower conversion costs across its business segments, while reaffirming expectations to reach the high end of its increased 2026 adjusted EBITDA guidance.

MarketBeat • Aug 12, 2026

NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue?

NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • Aug 4, 2026

NeoGenomics Q2 Earnings Call Highlights

NeoGenomics NASDAQ: NEO raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting second-quarter revenue growth that exceeded its prior outlook, led by higher-value clinical testing and continued expansion in next-generation sequencing.

MarketBeat • Jul 28, 2026

NeoGenomics, Inc. (NEO) Q2 2026 Earnings Call Transcript

NeoGenomics, Inc. (NEO) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jul 29, 2026

NeoGenomics Reports Second Quarter 2026 Results

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period ended June 30, 2026.

Business Wire • Jul 28, 2026

NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (the “Company”) (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has finalized a civil settlement with the Department of Justice (“DOJ”) on behalf of the Office of Inspector General of the U.S. Department of Health and Human Services (“OIG”) resolving an investigation concerning consulting services provided by the Company to certain health care providers for laboratory testing services as part of its Laboratory Collaboration Initiative program. The Company self-disclosed the matter to the OIG in November 2021. As the DOJ acknowledged in the settlement agreement, the Company cooperated with the government's investigation into the matter.

Business Wire • Jul 20, 2026

NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PTEN IHC CDx, the first IHC companion diagnostic test approved by the U.S. FDA for patients with prostate adenocarcinoma.

Business Wire • Jul 9, 2026

NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026.

Business Wire • Jul 7, 2026

NeoGenomics Appoints Carolyn Starrett to its Board of Directors

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Carolyn Starrett to its Board of Directors.

Business Wire • Jun 25, 2026

NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock?

NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • Jun 19, 2026